Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer Thomas John, MBBS, PhD, Naoki.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Primary Mucoepidermoid Carcinoma of the Esophagus

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study Thomas.

ALK FISH and IHC: You Cannot Have One without the Other

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine Stéphane Collaud, MD, MSc, Thomas K.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Survival after resection of synchronous non–small cell lung cancer

A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer Peter M. Ellis, MBBS,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor.

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Primary Mucoepidermoid Carcinoma of the Esophagus

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Erratum Journal of Thoracic Oncology

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study Marcello Carlo Ambrogi,

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

It’s All in the “Swerve of the Curve”

Pulmonary Resection for Metastases from Colorectal Cancer

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer Giorgio.

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material Eugen C. Minca, MD, PhD, Christopher P. Lanigan,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer Thomas John, MBBS, PhD, Naoki Yanagawa, MD, Derek Kohler, MD, Kenneth J. Craddock, MD, Bizhan Bandarchi-Chamkhaleh, MD, Melania Pintilie, MSc, Jenna Sykes, MMath, Christine To, MSc, Ming Li, MD, Devang Panchal, BVSc, Weisan Chen, PhD, Frances A. Shepherd, MD, Ming-Sound Tsao, MD Journal of Thoracic Oncology Volume 7, Issue 7, Pages 1101-1108 (July 2012) DOI: 10.1097/JTO.0b013e3182519d4d Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Distinguishing human from murine DLBCLs in xenograft specimens. HE stains from a human (A) and murine (C) DLBCL. The SISH images (B and D) confirm the presence of human chromosome 7 in B but not D. DLBCL, diffuse large B-cell lymphomas; HE, Hematoxylin-Eosin; SISH, silver in situ hybridization. Journal of Thoracic Oncology 2012 7, 1101-1108DOI: (10.1097/JTO.0b013e3182519d4d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Representative images of DLBCL IHC for one case. CD20 (A), CD79a (B), CD3 (C), kappa light chain (D), lambda light chain (E), and MIB-1 (F). DLBCL, diffuse large B-cell lymphomas; IHC, immunohistochemistry. Journal of Thoracic Oncology 2012 7, 1101-1108DOI: (10.1097/JTO.0b013e3182519d4d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier disease-free and overall survival curves comparing all XG, no-XG, and diffuse large B-cell lymphoma (DLBCL) groups (A and C) and those with adenocarcinoma lung primaries (B and D) demonstrating improved disease-free survival (DFS) and a trend toward overall survival in the DLBCL patients compared with XG patients. DFS in patients wild-type for EGFR in the entire cohort (E) and in the group with adenocarcinoma (F). DLBCL, diffuse large B-cell lymphomas; XG, xenograft; no-XG, non-engrafting. Journal of Thoracic Oncology 2012 7, 1101-1108DOI: (10.1097/JTO.0b013e3182519d4d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions